Get these analyses to your inbox — https://axialobservations.substack.com/ This is a newsletter for rough-around-the-edges ideas. More well thought out work can be found at — https://axial.substack.com/
Axial invests and partners in early-stage life sciences companies. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company — info@axialsprawl.com
New medicines #4 — May 30, 2020 — June 5, 2020
A weekly overview of the development of new medicines.
- Adamas announced FDA filing acceptance of its NDA for Gocovri as a treatment for OFF episodes in Parkinson’s patients receiving levodopa-based therapy:
- Amyndas received FDA approval to start its Phase 2 clinical study (144 patients) evaluating the efficacy of AMY-101 (C3 inhibitor) in COVID-19 patients with ARDS — https://www.amyndas.com/covid-19/
- Boehringer Ingelheim reported an update on its phase 1 clinical trial of its pan-KRAS inhibitor (BI 1701963):
- 3 patients have been treated as of 02/11/20
